The Protective Barrier of SYMTUZA

SYMTUZA™ is the only STR with the protective barrier of darunavir

Zero Treatment Emergent

Zero treatment-emergent darunavir, primary PI, or TAF mutations across clinical trial populations1*

Only 1 patient receiving SYMTUZA™ was found to have M184I/V; this patient also had a transmitted K103N mutation at screening. M184V was detected pretreatment by deep sequencing (Illumina MiSeq) as a minority variant (9.4%).2

Modular Properties
Darunavir Targets HIV Differently

SYMTUZA™ has the Ability to Adapt to HIV-1 Protease Mutations3

Tightly binds and adapts to mutant HIV-1 protease3-6

LEARN MORE

Darunavir Kinetic Profile

Darunavir Kinetic Profile Results in Strong Protease Binding3

Darunavir has a fast association rate, slow dissociation rate, and high binding affinity

LEARN MORE

Darunavir Plasma Concentration

SYMTUZA™ Maintains Darunavir Plasma Concentrations1,7

33X greater than EC50 at 24 hours1,2‡§

LEARN MORE

The clinical implications of these data have not been established.

*In the AMBER trial, of 362 treatment-naïve patients taking SYMTUZA™, 8 met the criteria for VF and 7 patients experiencing VF were analyzed for resistance.

In the EMERALD trial, of 763 virologically suppressed patients taking SYMTUZA™, 6 met the criteria for VF and 1 patient experiencing VF was analyzed for resistance.

From population PK analysis in SYMTUZA™ Phase 3 study in ARV-naïve subjects (n=355).

§From population PK analysis in SYMTUZA™ Phase 3 study in ARV-experienced subjects (n=750).

 

 

Extensive Experience
Darunavir Overtime

Protective Barrier

that has been proven over time8,9

LEARN MORE

Greater one in four

>1 in 4 Patients

diagnosed and living with HIV-1 who were on treatment received a darunavir-based regimen in 20177

4500 Patients

>4500 Patients

treated with darunavir in 12 clinical trials, with data up to 192 weeks1,7,10-16

million-prescriptions

>6.4 Million Prescriptions

with darunavir in the United States since approval7

AMBER TN (n=362); EMERALD TE (n=763); ARTEMIS TN (n=343); Study 130 TN and TE (n=295, n=18); ODIN TE (n=294); ODIN TE BID (n=296); POWER 1 TE (n=65); POWER 2 TE (n=66); POWER 3 TE (n=336); METABOLIK TN (n=14); GRACE TE (n=492); DUET TE (n=999); TITAN TE (n=298) = 4641.

SYMTUZA™ Has the Ability to Adapt to HIV-1 Protease Mutations
SYMTUZA™ contains darunavir, which quickly and tightly binds to HIV-1 protease3-6
Fits tightly into the viral protease pocket and forms an extensive network of long-lasting hydrogen-bonding interactions
No DRV, Primary PI, or Tenofovir RAMs in 1125 study participants
Molecular flexibility allows for adaptation to mutant HIV-1 protease, maintaining these bonds and preserving antiretroviral activity
  • SYMTUZA™ should not be used in patients with known DRV RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V, and L89V) or mutations to tenofovir

The clinical implications of these data have not been established.

 

BACK TO TOP

Darunavir Kinetic Profile Results in Strong Protease Binding3
Darunavir has a fast association rate, slow dissociation rate, and high binding affinity#
Fast Association Rate
Fast Association Rate

(kon) = (2.2 + 0.8) x 106

  • Association Rate (kon) = The degree of recognition a molecule has for HIV
Slow Dissociation Rate
Slow Dissociation Rate

(koff) = (7.8 + 0.5) x 10-7

  • Dissociation Rate (koff) = The binding stability of the interaction between a molecule and HIV

Dissociative half-life >240 hours

High Binding Affinity
High Binding Affinity

(kD) = (4.1 + 1.7) x 10-13

  • Binding Affinity (kD) = The ratio of kon to koff

Calculation: koff/kon = KD

The clinical implications of these data have not been established.

#Measurements were assessed using wild-type virus.

BACK TO TOP

SYMTUZA™ Maintains Therapeutic Darunavir Plasma Concentrations 33 Times Greater Than EC50 Over 24 Hours1,7
Plasma concentrations 33 times grater

 

The clinical implications of these data have not been established.

Infographic is for graphical representation only.

 

BACK TO TOP

Protective Barrier That Has Been Proven Over Time
In 2 extensive retrospective analyses of isolates, darunavir RAMs decreased over time8,9**††
Protective Barrier That Has Been Proven Over Time

 

The absence of darunavir RAMs does not imply clinical results.

**Study Design 1: the aim of this analysis was to assess potential changes in the frequency trends of darunavir RAMs over time in the United States. Clinical isolates (N=78,843) submitted to Monogram Biosciences for routine clinical resistance testing (PhotoSense GT®) between January 2006 and June 2012 were analyzed. The proportion of samples with 0, 1, 2, and ≥3 RAMs were evaluated at yearly intervals between 2006 and the first half of 2012.

††Study Design 2: the aim of this analysis was to evaluate DRV and primary Pl RAMs and phenotypic resistance among clinical samples in the United States. Clinical isolates (N=48,786) submitted to Monogram Biosciences for routine clinical resistance testing (PhotoSense GT®) between January 2010 and December 2015 were analyzed. The proportion of samples with 0, 1, 2, and 3 RAMs were evaluated at yearly intervals between 2010 and 2015.

‡‡Darunavir RAMS=V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V.

§§Statistical trend analysis demonstrated a significant upward trend, P=0.0008.

Statistical trend analysis demonstrated a significant downward trend, P=0.002.

BACK TO TOP

PhotoSense GT® is a registered trademark of Monogram Biosciences.

ARV=antiretroviral; CO=mean trough plasma population; DRV/r=darunavir/ritonavir; DTG=dolutegravir; EC50=half maximal effective concentration; FTC=emtricitabine; H1=first half; PK=pharmacokinetics; Pl=protease inhibitor; RAMs=resistance-associated mutations; STR=single-tablet regimen; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate; VF=virologic failure.

References: 1. SYMTUZA™ [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP. 2. Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat /emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. AIDS. 2018;32:1431-1442. 3. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral acti vity and high genetic barrier. J Viral. 2007;81:13845-13851. 4. Ghosh AK, Anderson DD, Weber IT, Mitsuya H. Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed. 2012;1778-1802. 5. Tremblay CL. Combating HIV resistance-focus on darunavir. Ther Clin Risk Manag. 2008;4:759-765. 6. King NM, Prabu-Jeyabalan M, Nalivaika EA. et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Viral. 2004;78:12012-12021. 7. Data on file. Janssen Therapeutics, Division of Janssen Products, LP. 8. Lathouwers E, Gupta S, Haddad M, et al. Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012. AIDS Res Hum Retroviruses. 2015;31:628-635. 9. Brown K, Stewart L, Whitcomb JM, et al. Prevalence of darunavir resistance in the United States (2010-2015). Poster presented at the 9th International AIDS Society (IAS) Conference; July 23-26, 2017; Paris, France. 10. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14:49-59. 11. Cahn P, Fourie J, Grinsztejn B, et al. 48-week analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25:929-939. 12. Arastéh i K, Yeni iP, Pozniak A, et al. Efficacy and safety  of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14:859-864. 13. Aberg JA, Tebas P, Overton ET. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type-1 infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28:1184-1195. 14. Currier J, Bridge DA. Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-357 15. Katlama C, Clotet B, Mills A. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;(15):1045-1052. 16. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase Ill trial. Lancet. 2007;370(9581):49-58.